Argos Therapeutics, Inc. Announces Issuance Of Arcelis® Technology Platform Patent
DURHAM, N.C., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,822,223 related to the Argos Arcelis® technology platform and the company's AGS-003 and AGS-004 immunotherapies. The patent will expire in 2025, excluding any possible patent term extensions.
According to Jeff Abbey, chief executive officer at Argos, "This patent significantly expands the protection of our proprietary Arcelis® technology platform relating to the maturation method used in the manufacture of our dendritic cell immunotherapies for treatment of cancer and infectious disease. This patent relates to production of our two lead investigational immunotherapies, AGS-003 for metastatic renal cell carcinoma (mRCC) and AGS-004 for HIV infection."
"This patent covers production methods that make the Arcelis® platform fundamentally different from other dendritic cell-based immunotherapies. Our approach is based on a well-defined mechanism of action resulting in the inducement of patient and disease specific memory T cells, which has been shown to statistically correlate with clinical outcomes," said Charles Nicolette, chief scientific officer at Argos.
About the Arcelis® Technology Platform
Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.
The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company also plans to report data from its phase 2b clinical trial of AGS-004 for the treatment of HIV in the third quarter of 2014. AGS-004 is currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
CONTACT: Media: Jen Ringler Berry & Company Public Relations jringler@berrypr.com (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan akolhatkar@burnsmc.com (212) 213-0006 